Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Department of Radiation Biology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Sci Rep. 2024 Mar 28;14(1):7433. doi: 10.1038/s41598-024-58233-1.
Epstein-Barr virus (EBV) encoded microRNA BART8-3p (miR-BART8-3p) was significantly associated with the metastasis in nasopharyngeal carcinoma (NPC). To explore the clinical values of plasma miR-BART8-3p in patients with early NPC. We retrospectively analyzed 126 patients with stage I and II NPC. A receiver operating characteristic curve was used to examine the diagnostic performance. Kaplan‒Meier analysis was applied to determine survival differences. Cox regression was used for univariate and multivariate analyses. Compared to healthy subjects, plasma EBV miR-BART8-3p was highly expressed in early NPC patients. The sensitivity, specificity, and area under the curve value of plasma miR-BART8-3p combined with plasma EBV DNA was up to 88.9%, 94.4%, and 0.931. Compared to patients with low expression of miR-BART8-3p, patients with high expression of miR-BART8-3p had poorer 5-year overall survival (OS) (98.9% vs. 91.1%, P = 0.025), locoregional recurrence-free survival (LRRFS) (100% vs. 83.9%, P < 0.001) and distant metastasis-free survival (DMFS) (98.9% vs. 88.0%, P = 0.006). Risk stratification analysis revealed that high-risk patients (with high levels of EBV DNA and miR-BART8-3p) had inferior OS, LRRFS, and DMFS than low-risk patients (without high levels of EBV DNA and miR-BART8-3p). Multivariate analysis verified that the high-risk group was an unfavorable factor for OS, LRRFS, and DMFS. A combination of plasma EBV miR-BART8-3p and EBV DNA could be a potential biomarker for the diagnosis and prognosis in early NPC.
Epstein-Barr 病毒（EBV）编码的 microRNA BART8-3p（miR-BART8-3p）与鼻咽癌（NPC）的转移显著相关。为了探讨血浆 miR-BART8-3p 在早期 NPC 患者中的临床价值。我们回顾性分析了 126 例 I 期和 II 期 NPC 患者。采用受试者工作特征曲线（ROC）来检验诊断性能。Kaplan-Meier 分析用于确定生存差异。Cox 回归用于单因素和多因素分析。与健康受试者相比，早期 NPC 患者的血浆 EBV miR-BART8-3p 表达水平较高。血浆 miR-BART8-3p 联合 EBV DNA 的灵敏度、特异度和曲线下面积值高达 88.9%、94.4%和 0.931。与 miR-BART8-3p 低表达的患者相比，miR-BART8-3p 高表达的患者 5 年总生存率（OS）较差（98.9%比 91.1%，P=0.025），无局部区域复发生存（LRRFS）（100%比 83.9%，P<0.001）和无远处转移生存（DMFS）（98.9%比 88.0%，P=0.006）。风险分层分析显示，高危患者（高 EBV DNA 和 miR-BART8-3p 水平）的 OS、LRRFS 和 DMFS 低于低危患者（无高 EBV DNA 和 miR-BART8-3p 水平）。多因素分析证实高危组是 OS、LRRFS 和 DMFS 的不利因素。血浆 EBV miR-BART8-3p 联合 EBV DNA 可能是早期 NPC 诊断和预后的潜在生物标志物。
